Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Исследование адаптивной платформы при хронических заболеваниях почек, изучающее различные агенты на предмет терапевтического эффекта (CAPTIVATE)

29 сентября 2026 г. обновлено: The George Institute

CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).

CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure.

CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.

CAPTIVATE includes multiple domains examining different therapies for CKD. Participants may enrol in one or more domains and domains will be added and closed over time. The platform operates under a core protocol with each domain described in a domain specific appendix.

Обзор исследования

Подробное описание

Chronic kidney disease (CKD) affects over 800 million people globally and is projected to be the 5th most common cause of death by 2040. CKD progresses to kidney failure, increases the risk of early death, heart disease, and leads to a poorer quality of life.

Current treatments do not entirely remove the risk of kidney failure in people with CKD. To improve the outcomes of people with CKD, it is crucial to find the best treatment or combination of treatments that can slow CKD progression. CAPTIVATE aims to address this need.

CAPTIVATE has been designed to test multiple treatments within a common research platform. This design is more efficient and will lead to a shorter time for patients to receive effective treatments. The trial is 'eternal', which means that participants will continue to be recruited for many years until the trial is finally wound up. It is also 'adaptive', providing the flexibility to add new treatments, or remove those that are not working.

Participants can participate in more than one treatment at the same time or at different times. Participants receive each study treatment for 2 years. For each treatment, participants are followed up at study visits that occur at approximately one month, 3 months, 6 months, 12 months, 18 months and 2 years after starting treatment. A final study visit occurs one month after the end of the 2-year treatment phase. Information collected at study visits include blood and urine test results, safety assessments and treatment adherence. Information about the overall health status of each participant is collected every 5 years.

Тип исследования

Интервенционный

Регистрация (Оцененный)

2000

Фаза

  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

Места учебы

    • Australian Capital Territory
      • Garran, Australian Capital Territory, Австралия, 2605
        • Рекрутинг
        • The Canberra Hospital
        • Контакт:
          • Girish Talaulikar
    • New South Wales
      • Kingswood, New South Wales, Австралия, 2747
        • Рекрутинг
        • Nepean Blue Mountains Local Health District
        • Контакт:
          • Bhadran Bose
      • Kogarah, New South Wales, Австралия, 2217
        • Рекрутинг
        • St George Hospital
        • Контакт:
          • Sunil Badve
      • New Lambton Heights, New South Wales, Австралия, 2305
        • Рекрутинг
        • John Hunter Hospital
        • Контакт:
          • Bobby Chacko
      • Westmead, New South Wales, Австралия, 2145
        • Рекрутинг
        • Westmead Hospital
        • Контакт:
          • Vincent Lee
    • Queensland
      • Birtinya, Queensland, Австралия, 4575
        • Рекрутинг
        • Sunshine Coast Hospital and Health Service
        • Контакт:
          • Nicholas Gray
      • Douglas, Queensland, Австралия, 4814
        • Рекрутинг
        • Townsville University Hospital
        • Контакт:
          • Vikas Srivastava
      • Ipswich, Queensland, Австралия, 4305
        • Рекрутинг
        • West Moreton Hospital & Health Service
        • Контакт:
          • Sree Venuthurupalli
      • Southport, Queensland, Австралия, 4215
        • Рекрутинг
        • Gold Coast Hospital and Health Service
        • Контакт:
          • Jagadeesh Kurtkoti
    • South Australia
      • Adelaide, South Australia, Австралия, 5000
        • Рекрутинг
        • Royal Adelaide
        • Контакт:
          • Michael Collins
      • Elizabeth Vale, South Australia, Австралия, 5112
        • Рекрутинг
        • Lyell McEwin Hospital
        • Контакт:
          • Nitesh Rao
    • Victoria
      • Heidelberg, Victoria, Австралия, 3084
        • Рекрутинг
        • Austin Health
        • Контакт:
          • Sharon Ford
    • Western Australia
      • Murdoch, Western Australia, Австралия, 6150
        • Рекрутинг
        • South Metropolitan Health Service, Fiona Stanley Hospital
        • Контакт:
          • Suda Swaminathan
      • Dehradun, Индия, 248001
        • Еще не набирают
        • Max Superspeciality Hospital, Dehradun
        • Контакт:
          • Puneet Arora
      • Ghaziabad, Индия, 201012
        • Рекрутинг
        • Max Superspecialty Hospital, Ghaziabad
        • Контакт:
          • Manoj Kumar Singhal
      • Puducherry, Индия, 607403
        • Рекрутинг
        • Aarupadai Veedu Medical College & Hospital (AVMCH), Puducherry
        • Контакт:
          • Venkatesh A
    • Andhra Pradesh
      • Visakhapatnam, Andhra Pradesh, Индия, 530045
        • Рекрутинг
        • Gitam Institute of Medical Sciences and Research
        • Контакт:
          • Murty Mandapaka
    • Bihar
      • Patna, Bihar, Индия, 800001
        • Рекрутинг
        • Patna Medical College and Hospital
        • Контакт:
          • Harsh Vardhan
    • Chhattisgarh
      • Raipur, Chhattisgarh, Индия, 492002
        • Рекрутинг
        • DKS Super Speciality Hospital, Raipur
        • Контакт:
          • Varun Agrawal
    • Dehradun
      • Dehradun, Dehradun, Индия, 248001
        • Рекрутинг
        • Mysore Medical College
        • Контакт:
          • Puneet Arora
    • Gujarat
      • Ahmedabad, Gujarat, Индия, 380025
        • Рекрутинг
        • GCS Medical College, Hospital & Research Centre
        • Контакт:
          • Suvika Patel
      • Vadodara, Gujarat, Индия, 390007
        • Рекрутинг
        • Aman Hospital & Research Center Vadodara
        • Контакт:
          • Aman Khanna
    • Karnataka
      • Mangaluru, Karnataka, Индия, 575002
        • Рекрутинг
        • Father Muller Medical College Hospital
        • Контакт:
          • Manjunath Kulkarni
    • Kerala
      • Meppādi, Kerala, Индия, 673511
        • Рекрутинг
        • Dr Moopen's Medical College
        • Контакт:
          • Aneesh Basheer
    • Madhya Pradesh
      • Indore, Madhya Pradesh, Индия
        • Рекрутинг
        • CARE-CHL Hospital
        • Контакт:
          • Isha Tiiwari
    • Tamil Nadu
      • Chennai, Tamil Nadu, Индия, 600024
        • Рекрутинг
        • Medway Hospital
        • Контакт:
          • Shivakumar Dakshinamoorthy
    • Telangana
      • Hyderabad, Telangana, Индия, 500084
        • Рекрутинг
        • Yashoda Hospital Hitec City
        • Контакт:
          • Mahesh Kota
      • Hyderabad, Telangana, Индия
        • Рекрутинг
        • Apollo Hospitals
        • Контакт:
          • Haresh Patel
    • Uttar Pradesh
      • Lucknow, Uttar Pradesh, Индия, 226003
        • Рекрутинг
        • Charak Hospital and Research Centre
        • Контакт:
          • Sakshi Jain
    • Uttarakhand
      • Dehradun, Uttarakhand, Индия, 248001
        • Рекрутинг
        • Shri Guru Ram Rai Medical College and Shri Mahant Indiresh Hospital
        • Контакт:
          • Gaurav Shekhar Sharma
    • West Bengal
      • Kolkata, West Bengal, Индия, 700107
        • Рекрутинг
        • Fortis Hospital
        • Контакт:
          • Upal Sengupta
      • Siliguri, West Bengal, Индия, 734012
        • Рекрутинг
        • North Bengal Medical College & Hospital
        • Контакт:
          • Arpita Ray Chaudhury
    • Barcelona
      • Badalona, Barcelona, Испания, 08916
        • Активный, не рекрутирующий
        • Hospital Germans Trias i Pujol
      • Horta-Guinardó, Barcelona, Испания, 08035
        • Рекрутинг
        • Vall d'Hebron University Hospital
        • Контакт:
          • Dr Maria Jose Soler Romeo
    • Espana
      • Valencia, Espana, Испания, 46010
        • Рекрутинг
        • Hospital Clinico Universitario València (INCLIVA)
        • Контакт:
          • Prof Jose Luis Gorriz Teruel
      • Auckland, Новая Зеландия, 1023
        • Рекрутинг
        • Auckland City Hospital
        • Контакт:
          • Dr Helen Pilmore
      • Auckland, Новая Зеландия, 2025
        • Рекрутинг
        • Aotearoa Clinical Trials Trust, Middlemore Hospital
        • Контакт:
          • Kalpa Jayanatha
      • Auckland, Новая Зеландия, 0620
        • Рекрутинг
        • Health New Zealand, Te Whatu Ora Waitemata, North Shore Hospital
        • Контакт:
          • Ashik Hayat
      • Dunedin, Новая Зеландия, 9016
        • Рекрутинг
        • 201 Great King Street, Central Dunedin, Dunedin 9016, New Zealand
        • Контакт:
          • John Schollum
      • Palmerston North, Новая Зеландия, 4442
        • Рекрутинг
        • Midcentral - Palmerston North Hospital
        • Контакт:
          • Dr Curtis Walker
      • Whangarei, Новая Зеландия, 0148
        • Рекрутинг
        • Private Bag 9742 Maunu Road, Horahora, Whangārei 0148, New Zealand
        • Контакт:
          • Adam Mullan
    • Hawkes Bay
      • Hastings, Hawkes Bay, Новая Зеландия, 4120
        • Рекрутинг
        • Health New Zealand, Te Whatu Ora Te Matau a Maui, Hawke's Bay Hospital
        • Контакт:
          • Hussain Allawati
      • Colombo, Шри-Ланка, 00700
        • Рекрутинг
        • National Hospital of Sri Lanka
        • Контакт:
          • Dr Mathu Selvarajah
      • Kandy, Шри-Ланка, 20000
        • Рекрутинг
        • Kandy National Hospital
        • Контакт:
          • Dr Nishantha Nanayakkara
      • Kurunegala, Шри-Ланка
        • Рекрутинг
        • Kurunegala Teaching Hospital
        • Контакт:
          • Dr Premil Rajakrishnan
      • Nugegoda, Шри-Ланка, 10250
        • Рекрутинг
        • Sri Jayewardenepura General Hospital
        • Контакт:
          • Dr Harshani Perera
      • Peradeniya, Шри-Ланка, 20400
        • Рекрутинг
        • Peradeniya Teaching Hospital
        • Контакт:
          • Dr Rajitha Abeysekera
      • Ragama, Шри-Ланка, 11010
        • Рекрутинг
        • Colombo North Teaching Hospital
        • Контакт:
          • Dr Nalaka Herath
    • Northern Province
      • Jaffna, Northern Province, Шри-Ланка, 4000
        • Рекрутинг
        • Jaffna Teaching Hospital
        • Контакт:
          • Dr. Brammah Thangarajah
    • Polonnaruwa
      • Colombo, Polonnaruwa, Шри-Ланка, 51000
        • Рекрутинг
        • National Nephrology Specialized Hospital
        • Контакт:
          • Dr Naseef Thaseem
    • Western Province
      • Dehiwala, Western Province, Шри-Ланка, 10290
        • Рекрутинг
        • University Hospital, Kotelawala Defence University
        • Контакт:
          • Dr Dilukshi Pilapitiya

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m2)
  3. Currently receiving standard of care treatment according to treating physician
  4. Eligible for randomisation in at least one recruiting domain-specific appendix
  5. Participant and treating physician are willing and able to perform trial procedures

Exclusion Criteria:

  1. Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months
  2. Life expectancy less than 6 months

To be included in any of the following DOMAINS the participant must met eligible for the PLATFORM (as listed above)

MRA domain

Inclusion Criteria:

  1. Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine protein-creatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
  2. On a stable standard of care treatment for CKD, including a SGLT2i unless there is a documented reason not to be using a SGLT2i*, for 4 weeks before screening according to treating physician.
  3. Treating physician believes finerenone is clinically appropriate for the participant.
  4. Participant and treating physician are willing and able to perform MRA DSA procedures.
  5. Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any MRA DSA related procedures

Exclusion Criteria:

  1. Recipient of kidney transplant
  2. Hyperkalaemia (serum potassium ≥5.0 mmol/L) at time of screening
  3. Current treatment with MRA, where the treating physician or patient is not willing to discontinue this medication. If willing to discontinue the MRA, the potential participant must be re-screened after they have been on stable standard of care treatment for 4 weeks without the MRA.
  4. Known allergy, intolerance or contraindication to MRAs
  5. Current treatment with strong CYP3A4 inhibitors
  6. Systolic BP <110 mmHg or diastolic BP<55 mmHg without antihypertensive therapy at time of screening
  7. Severe hepatic impairment (defined as Child-Pugh Class C)
  8. Adrenal insufficiency
  9. Currently pregnant or breast feeding, or intending to become pregnant

GLP-1 RA Domain

Inclusion Criteria

  1. Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine proteincreatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
  2. On a stable standard of care treatment for CKD, including a SGLT2i and maximum tolerated ACEi/ARB unless there is a documented reason not to be using a SGLT2i, for 4 weeks before screening.
  3. HbA1c less than or equal to 10% (less than or equal to 86mmol/L)
  4. BMI ≥23 kg/m2 and < 50 kg/m2
  5. Treating physician believes semaglutide is clinically appropriate for the participant
  6. Participant and treating physician are willing and able to perform GLP-1 RA DSA procedures
  7. Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any GLP-1 RA DSA related procedures

Exclusion Criteria

  1. Recipient of kidney transplant
  2. Major adverse cardiovascular events (MACE), consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, within 90 days prior to the day of screening
  3. Presently classified as being in New York Heart Association (NYHA) Class IV heart failure
  4. Personal or first-degree relative(s) with a history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC)
  5. Previous episode of pancreatitis
  6. Uncontrolled thyroid disease TSH>6.0 mIU/L or <0.4mlU/L
  7. Type 1 diabetes
  8. Current treatment with a GLP-1 RA, where it is in the participant's best interests to continue the GLP-1 RA or where the treating physician or patient is not willing to discontinue this medication for a minimum of 4 weeks prior to randomisation and for the full duration of the trial (ie. 108 weeks if assigned to placebo).
  9. Known allergy, intolerance, or contraindication to GLP-1 RAs
  10. Currently pregnant or breast feeding, or intending to become pregnant or is of child-bearing potential, and not using a highly effective contraceptive method
  11. Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Факторное присвоение
  • Маскировка: Четырехместный

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Finerenone

Finerenone 10mg or 20mg tablets

Finerenone 10mg or 20mg tablets, oral, once daily

Другие имена:
  • BAY94-8862
Плацебо Компаратор: Placebo Finerenone

Finerenone matched placebo tablets

Finerenone matched placebo tablets, oral, once daily

Экспериментальный: Semaglutide

Semaglutide 1.0 mg or 2.4 mg pen injector

Semaglutide 1.0mg or 2.4mg pen injector, subcutaneous injection, once weekly

Плацебо Компаратор: Placebo Semaglutide

Semaglutide matched placebo pen injector

Semaglutide matched pen injector, subcutaneous injection, once weekly

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Core Primary Outcome Measure
Временное ограничение: From randomisation to week 108

The primary outcome is chronic eGFR slope. Chronic eGFR slope measures the rate of eGFR decline while on treatment. The duration of time over which chronic eGFR slope is computed can vary by domain and is determined by clinical considerations such as whether the investigational product can cause an acute decline in eGFR upon initiation. DSAs will specify the duration of time over which chronic eGFR slope is computed for the individual domain.

From randomisation to week 108
MRA Domain Primary Outcome Measure
Временное ограничение: From week 4 to week 108

Chronic eGFR slope estimated from all available eGFR values from week 4 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment.

From week 4 to week 108
GLP1-RA Domain Primary Outcome Measure
Временное ограничение: From week 0 to week 108

Chronic eGFR slope estimated from all available eGFR values from Week 0 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment.

From week 0 to week 108

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Core Protocol Secondary outcomes
Временное ограничение: week 0 and 24 weeks

1. Change in albuminuria as measured by uACR (or uPCR if uACR unavailable) between week 0 and 24 weeks, measured as a continuous variable.

week 0 and 24 weeks
Core Protocol Secondary outcomes
Временное ограничение: week 0 to end of washout

2. eGFR slope from week 0 to end of washout

week 0 to end of washout
Core Protocol Secondary outcomes
Временное ограничение: week 0 to end of washout

3. Change in eGFR from week 0 to end of washout

week 0 to end of washout
Core Protocol Secondary outcomes
Временное ограничение: between week 0 and 108 weeks

4. Composite outcome of proportion of participants experiencing a ≥40% eGFR decline between week 0 and 108 weeks, and proportion of participants developing kidney failure (defined as eGFR <15 mL/min/1.73m2 or chronic kidney replacement therapy start†) at 108 weeks.

between week 0 and 108 weeks
Core Protocol Secondary outcomes
Временное ограничение: from start of study drug (week 0) to washout (week 108) or kidney failure

5. Time to a composite outcome of ≥40% eGFR decline from week 0 or kidney failure

from start of study drug (week 0) to washout (week 108) or kidney failure
Core Protocol Secondary outcomes
Временное ограничение: at 108 weeks

6. All-cause mortality at 108 weeks

at 108 weeks
Core Protocol Secondary outcomes
Временное ограничение: between week 0 and week 108

7. Proportion of participants experiencing one or more cardiovascular events (cardiovascular death, hospitalised heart failure, myocardial infarction, stroke)* between week 0 and week 108

between week 0 and week 108
Core Protocol Secondary outcomes
Временное ограничение: from start of study drug (week 0) to end of washout (week 108)

8. Time to first occurrence of a cardiovascular event

from start of study drug (week 0) to end of washout (week 108)
Core Protocol Secondary outcomes
Временное ограничение: from start of study drug (week 0) to end of treatment (up to week 104)

9. Safety and tolerability of treatment

from start of study drug (week 0) to end of treatment (up to week 104)
Core Protocol Secondary outcomes
Временное ограничение: 6-monthly intervals from randomisation to week 108

10. Change in quality of life measured using the Quality of Life Impact Survey for Kidney Disease (QDISCKD) at 6-monthly intervals from randomisation to week 108.

6-monthly intervals from randomisation to week 108
MRA Domain Secondary Outcome
Временное ограничение: from start of study drug (week 0) to end of washout (week 108)

MRA DSA has a domain-specific secondary outcome that evaluates the time to the composite of ≥57% eGFR decline from week 0 or kidney failure

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Временное ограничение: from start of study drug (week 0) to end of washout (week 108)

1. Change in eGFR slope from Week 0 to Week 108.

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Временное ограничение: from start of study drug (week 0) to end of washout (week 108)

2. Time to composite of onset of kidney failure (initiation of long-term dialysis, kidney transplantation, or a reduction in the eGFR to <15 mL per minute per 1.73 m2 sustained for ≥28 days), a sustained (for ≥28 days) 50% or greater reduction in eGFR from Week 0, or death from kidney-related or cardiovascular causes.

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Временное ограничение: from Week 0 to Week 108

3. Time to first occurrence of onset of persistent ≥50% reduction in eGFR from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Временное ограничение: from start of study drug (week 0) to end of washout (week 108)

4. Time to first occurrence of a composite outcome of major adverse cardiovascular events (MACE) consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Временное ограничение: from start of study drug (week 0) to end of washout (week 108)

5. Time to occurrence of all-cause death

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Временное ограничение: from Week 0 to Week 108

6. Change in body weight from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Временное ограничение: Week 0 to Week 108

7. Change in HbA1c from Week 0 to Week 108

Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Временное ограничение: from Week 0 to Week 108

8. Change in systolic blood/diastolic blood pressure from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Временное ограничение: from Week 0 to Week 108

9. Change in NT-proBNP from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Временное ограничение: from randomisation to Week 108

10. Change in health status measured using the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ) at 6-monthly intervals from randomisation to Week 108

from randomisation to Week 108
GLP-1 RA Domain Secondary Outcome
Временное ограничение: Week 0 to end of trial

11. Incidence of AEs and the following medical events of special interest (MESI) from Week 0 to end of trial:

  1. Neoplasm (malignant and benign)
  2. Pancreatitis, or persistent abdominal pain leading to a suspicion of pancreatitis
  3. Acute gallstone disease (biliary colic or acute cholecystitis)
  4. Thyroid disease
  5. Cardiac arrhythmia (specifically, atrial fibrillation, atrial flutter, ventricular tachycardia, ventricular fibrillation, torsade de pointes, second degree heart block type 2, third degree heart block, and symptomatic bradycardia requiring pacemaker placement)
  6. Severe hypoglycaemic episodes
  7. Immunogenicity events (allergic reactions, immune-complex disease, and lack of efficacy)
  8. Adverse events leading to treatment discontinuation (if not any of the mentioned MESIs)
  9. Ocular adverse events
  10. Suspicion of transmission of infectious agents
Week 0 to end of trial

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Следователи

  • Учебный стул: Sradha Kotwal, The George Institute
  • Учебный стул: Hiddo Lambers Heerspink, The George Institute

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

4 сентября 2024 г.

Первичное завершение (Оцененный)

31 декабря 2029 г.

Завершение исследования (Оцененный)

31 декабря 2029 г.

Даты регистрации исследования

Первый отправленный

21 сентября 2023 г.

Впервые представлено, что соответствует критериям контроля качества

21 сентября 2023 г.

Первый опубликованный (Действительный)

28 сентября 2023 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

5 октября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

29 сентября 2026 г.

Последняя проверка

1 августа 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

Trial data will be made available as a resource for future unspecified research, subject to any prior contractual obligations. Researchers wishing to gain access to the study resources will be required to submit an application for review by the Platform Oversight Committee, including a detailed project description, a list of data requested, and evidence of ethical approval. De-identified data extracts will be made available to approved proposals, and will not include data obtained from data linkage with local registries.

Сроки обмена IPD

TBC

Критерии совместного доступа к IPD

Assessments of data requests will be based on sound science, benefit-risk balancing and research team expertise.

Совместное использование IPD Поддерживающий тип информации

  • STUDY_PROTOCOL
  • САП
  • МКФ
  • КСО

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться